MWNA
LONA

Marshall Wace North America’s LeonaBio Inc LONA Stock Holding History

Marshall Wace North America’s Portfolio LONA Stock Details LONA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,838
Closed -$709K – 1299
2020
Q3 		$709K Buy
+3,838
New +$641K ﹤0.01% 888

Other funds holding LONA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Marshall Wace North America's LONA Position: Q4 2020 in Review

Marshall Wace North America sold out of LeonaBio Inc (LONA) in Q4 2020, closing a stake of 3,838 shares — an estimated $709K sold.

Marshall Wace North America first reported a position in LONA in Q3 2020 and held it in 1 quarter. The position peaked at $709K in Q3 2020. 70 funds tracked by Wall St. Rank hold LONA as of Q4 2020.

  • Marshall Wace North America reported no remaining LeonaBio Inc position as of Q4 2020 after selling out during the quarter.
  • Marshall Wace North America sold 3,838 LeonaBio Inc shares in Q4 2020, an estimated $709K.
  • Marshall Wace North America first reported a position in LeonaBio Inc in Q3 2020 and held it in 1 quarter.
  • Marshall Wace North America's LeonaBio Inc position peaked at $709K in Q3 2020.
  • 70 funds tracked by Wall St. Rank held LeonaBio Inc as of Q4 2020.

Based on Marshall Wace North America's 13F filing for Q4 2020, filed 16 Feb 2021.